

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT ELECTION OF NEW CHAIRMAN AND CHANGE OF COMPOSITION OF BOARD COMMITTEE

Reference is made to the announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 12 January 2021 in relation to the resignation of the chairman of the Company. The board of directors (the “**Board**”) of the Company hereby announces that on 14 January 2021, the Board has elected executive director, Mr. Yu Qingming (“**Mr. Yu**”) as the chairman of the Board of the Company, the chairman of the strategy and investment committee of the Board and the chairman of the nomination committee of the Board with immediate effect; and elected Mr. Liu Yong (“**Mr. Liu**”) as the member of the legal and compliance and environmental, social and governance committee with immediate effect.

The biographical details of Mr. Yu and Mr. Liu are as below:

Mr. Yu Qingming, aged 57, Secretary of Party Committee, chairman and executive director. Mr. Yu has over 34 years of working experience in the pharmaceutical industry, especially in the management of pharmaceuticals, medical devices and healthcare products, and holds the professional title of chief senior engineer. Mr. Yu graduated from Shanghai Medical Instrumentation College (now known as Shanghai University of Medicine & Health Sciences) in 1987, and graduated from the Central Party School majoring in economic management in July 2001 with a master's degree. From July 1987 to April 1990, Mr. Yu successively held office in Beijing Pharmaceutical Station of CNPGC and China National Medical Equipment Industry Corporation. From April 1990 to February 1997, he served in the State Pharmaceutical Administration, serving as deputy principle clerk, principle clerk and deputy department secretary of the General Office. From February 1997 to December 2009, he successively served as deputy general manager of the China sales department and manager of the corporate management department, assistant to chairman, vice president and executive president of Zhuhai United Laboratories Co., Ltd. and executive president of United Laboratories International Holdings Limited. Mr. Yu was the director, general manager and party secretary of China National Medical Equipment Industry Corporation from December 2009 to August 2010.

Mr. Yu has taken senior management positions of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. since August 2010, and currently served as the chairman of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. Mr. Yu has served as secretary of party committee of the Company since November 2018, executive director of the Company since December 2018 and the chairman of the Company (legal representative) since 14 January 2021. Mr. Yu is currently also a representative of the 13th National People's Congress, a member of the 13th Committee of Chinese People's Political Consultative Conference in Chaoyang District, Beijing, vice president of China Association for Medical Devices Industry, vice chairman of China Association of Medical Equipment, and vice president of China Association for Vaccines, etc. He was also employed as a part-time professor of various colleges including East China University of Science and Technology.

Mr. Liu Yong, aged 52, executive Director, President and Deputy Secretary of Party Committee. Mr. Liu has over 29 years of working experience, over 26 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelor's degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a master's degree in business administration from Fudan University in January 2000 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999, and served as the deputy manager at the marketing department of China National Pharmaceutical Group Shanghai Co., Ltd. and the deputy general manager of Shanghai Guoda Pharmacy Chain Co., Ltd. from July 1999 to April 2003. Mr. Liu was the general manager and secretary of party committee of Sinopharm Group Shenyang Co., Ltd. from April 2003 to November 2009. Mr. Liu has served as vice president of the Company from January 2009 to November 2017, executive director and president of the Company since November 2017, and deputy secretary of party committee of the Company since January 2018; during this period, Mr. Liu served as general legal counsel of the Company from January 2014 to March 2018, and was also secretary to the Board of the Company from October 2016 to November 2017, joint company secretary and authorized representative of the Company from October 2016 to August 2018. Mr. Liu is also the director of Sinopharm Industrial Investment Co., Ltd. and China National Medicines Co., Ltd., and chairman of China National Accord Medicines Co., Ltd., and he also takes senior management positions at some subsidiaries.

Save as disclosed above and as at the date of this announcement, Mr. Yu and Mr. Liu do not have any relationships with any directors, senior management, substantial or controlling shareholder(s) of the Company, or hold any other positions in the Company or any of its subsidiaries, or any directorships in other listed companies in the last three years.

As at the date of this announcement, Mr. Yu holds 100,000 H shares of the Company, and Mr. Liu holds 69,300 H shares of the Company. Save as the information disclosed above, Mr. Yu and Mr. Liu do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, Mr. Yu and Mr. Liu will continue to be subject to the existing service agreements entered into with the Company and their terms of service will end on the expiration of the term of the current session of the Board. Pursuant to the articles of association of the Company, Mr. Yu and Mr. Liu will be subject to retirement by rotation and re-election upon the expiry of their terms of office. The

remuneration packages of Mr. Yu and Mr. Liu will be determined by the Board under the authorization granted at the annual general meeting of the Company after taking into account, among other things, the duties and responsibilities of Mr. Yu and Mr. Liu in the Company.

Save as disclosed herein, there are no matters in relation to the appointment of Mr. Yu and Mr. Liu that need to be brought to the attention of the shareholders of the Company nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Sinopharm Group Co. Ltd.
Wu Yijian
Joint Company Secretary

Shanghai, the PRC

14 January 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*